In this column for The Wall Street Journal’s Think Tank, Drew Altman discusses why high health care prices are a problem for consumers but not a cause of renewed growth in health spending.
- view as grid
- view as list
Web Event: Rx Drugs and the U.S. Health System: A Conversation about Medicare Prescription Drug Costs
On Wednesday, September 7, from noon to 1 p.m. ET, the Kaiser Family Foundation hosted a web conversation to discuss trends in Medicare prescription drug spending, as well as proposals to reduce costs and forecasts of what beneficiaries can expect in coming years.
This Visualizing Health Policy infographic with JAMA spotlights national spending on prescription drugs and the public’s views on pharmaceutical prices.
Webinar: How Might the Pandemic Affect Health Premiums, Utilization, and Outcomes in 2021 and Beyond?
As the coronavirus pandemic enters its eighth month, we are still facing uncertainty about what the long-term impact of the crisis will be for the health sector, and for patients. However, the extent to which costs grow, and how the burden is distributed across payers, programs, individuals, outcomes, and geography…
This summarizes key provisions of the No Surprises Act, enacted in December 2020 to address the problem of unexpected medical bills, and issues that could arise during implementation ahead of its Jan. 1, 2022 effective date.
This charticle draws on recent KFF poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices.
In his latest column for The Wall Street Journal’s Think Tank, Drew Altman discusses new poll findings showing very small numbers of consumers are using provider quality and price information. All previous columns by Drew Altman are available online.
In his latest column for The Wall Street Journal’s Think Tank, Drew Altman discusses why high health care prices are a problem for consumers, but not a cause of renewed growth in health spending. All previous columns by Drew Altman are available online.